Beone Medicines valuation
Secondary listing. The primary listing is BeOne Medicines · NASDAQ (USD)
$218.60Change from previous close: +3.02%Absolute change: +$6.40
Valuation
The P/E ratio is 63.0. The average price target of 17 analysts is $264.02.
Data as of October 5, 2026
Valuation multiples
- Market cap
- $312.06B
- Enterprise value
- $310.61B
- P/E (trailing 12 months)
- 63.0
- Forward P/E
- 30.9
- PEG
- 0.79
- Price/book
- 7.68
- Price/sales
- 50.9
- EV/EBITDA
- 289.9
- EV/revenue
- 50.7
Profitability and growth
- Gross margin
- 88.9%
- Operating margin
- 19.1%
- Net margin
- 10.7%
- ROE
- 14.7%
- ROA
- 7.5%
- ROIC
- 33.6%
- Revenue growth (year over year)
- 29.6%
- Earnings growth (year over year)
- 166.7%
Financial health
- Total cash
- $5.1B
- Total debt
- $2.05B
- Debt/equity
- 0.40
- Current ratio
- 3.41
- Quick ratio
- 2.91
- Altman Z-Score
- 5.65
- Piotroski F-Score
- 7.00
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $264.02
- Median price target
- $265.02
- High price target
- $321.80
- Low price target
- $226.07
- Analysts with a price target
- 17
- Consensus
- Strong buy
- Forward EPS
- $6.86
- EPS estimate, current year
- $0.62
Shares and trading
- Beta
- 0.52
- Average volume
- 4.29M
- Shares outstanding
- 1.36B
- Float
- 1.05B
- Institutional ownership
- 28.7%
- Insider ownership
- 13.8%
- Short ratio (days)
- 4.36